BridgeBio Pharma Wins FDA Approval for Heart Drug Rivaling Pfizer’s Vyndaqel
BridgeBio Pharma (BBIO) has received Food and Drug Administration approval for its heart drug, acoramidis, as a branded treatment called Attruby. This approval comes ahead of expectations, allowing BridgeBio to launch Attruby as a treatment for patients with transthyretin amyloid cardiomyopathy (ATTR-CM). In this condition, abnormal protein builds up on the heart, causing damage. The … Read more